The Share

The Diamyd Medical share is traded on Nasdaq First North Growth Market (ticker : DMYD B). ISIN code: SE0005162880.

About Nasdaq First North Growth Market

Nasdaq First North Growth Market is an alternative marketplace operated by an exchange within the Nasdaq Group. Companies on Nasdaq First North Growth Market are not subject to the same rules as companies on the regulated main market. Instead they are subject to a less extensive set of rules and regulations adjusted to small growth companies. The risk in investing in a company on Nasdaq First North Growth Market may therefore be higher than investing in a company on the main market. All companies with shares traded on Nasdaq First North Growth Market have a Certified Adviser who monitors that the rules are followed. The Exchange approves the application for admission to trading.

Certified Adviser at Nasdaq First North Growth Market

FNCA Sweden AB, Humlegårdsgatan 5, Box 5807, SE-102 48 Stockholm. Tel: 08-528 00 399, E-mail: info@fnca.se.

Analysts

Analysts following Diamyd Medical:
Maria Karlsson Osipova, DNB Carnegie . Maria.Karlsson.Osipova@dnbcarnegie.se

Annual Report

  December 2, 2025

Company Presentation

 July 15, 2025
Download PDF

CEO Comments

Read More
  Annual Report, November 13, 2025

Diamyd Medical is at the center of a major change in type 1 diabetes – a shift from managing the disease to influencing its progression. Our mission is clear: to restore the immune system’s balance through precision immunotherapy and help people preserve what nature intended – their endogenous insulin production.
By re-training the immune system to tolerate instead of attack, Diamyd® aims to preserve the body’s natural ability to produce insulin.
Ulf Hannelius, President and CEO

Calendar

  
Data pager
Data pager
12
January 12 − January 15, 2026
JP Morgan Healthcare Week
44th Annual J.P. Morgan Healthcare Conference, San Fransisco, USA.
January 28, 2026
Quarterly Report 1
Quarterly Report 1 2025/2026
March 3 − March 5, 2026
ASIT 2026
March 11 − March 14, 2026
ATTD 2026

The Story of Diamyd Medical

The company founder Anders Essen-Möller reveals the story behind the company's founding and his mission to stop Type 1 Diabetes in its tracks. The film also features board member Karin Hehenberger, shedding light on the patient’s perspective, and board member Dr. Mark Atkinson speaking of the importance of the enzyme GAD in Type 1 Diabetes.

“ If it was not for the hundreds of clinical sites and their personnel, investigators, patients, investors, not to mention the fantastic entrepreneurial, yet diligent, Diamyd team - this current transformational precision therapy for autoimmune diabetes based on genetics, should probably still remain undiscovered.
How can I thank you all ? "

- Anders Essen-Möller, Chairman of the Board
 

Diamyd Medical

Developing precision medicine therapies for the prevention and treatment of autoimmune diabetes

 

Ten largest shareholders as of September 30, 2025

ShareholderA SharesB SharesCapital %Votes %
Avanza Pension 16 463 835 11.97 9.74
Lindkvist, Bertil 8 965 500 6.52 5.30
Nordnet Pension 7 212 372 5.25 4.26
Essen-Möller, Anders * 1 135 620 3 119 040 3.09 8.56
Nordica Life 1 860 000 1.35 1.10
Essen-Möller, Maria-Teresa 400 000 963 998 0.99 2.93
Pictet and CIE (Eureope), Succurs, Ale de Lux 1 250 000 0.91 0.74
SEB Life International Insurance 1 056 347 0.77 0.62
Möller, Vidar 1 042 904 0.76 0.61
Konstruktions o Försäljningsaktiebolag 906 250 0.66 0.53
Remaining shareholders 1 967 500 91 156 357 67.73 65.56
Total 3 503 120 133 996 603 100.0 100.0
* Anders Essen-Möller also holds 2 178 152 class B-shares in an endowment policy and 100 000 class A-shares in a consulting company.

Order GAD for preclinical research

ORDER

Annual Report

  December 2, 2025
Annual Report cover image
Download

Contact Us

Diamyd Medical AB (publ)
Box 7349, SE-103 90 Stockholm
Visiting addresses:
Kungsgatan 29, SE-111 56 Stockholm
+46 8 661 00 26
Umeå:
Formvägen 7B, SE-906 21 Umeå

Subscribe

Follow Us

  ©
GAD PRODUCTS
Order GAD for preclinical research